Mesoblast Hits Patient Recruitment Target in Pivotal Phase 3 Chronic Low Back Pain Trial
MESO sits 55% above its 52-week low of $9.88 on light trading volume (0.3× avg).
Summary
Mesoblast announced it has achieved its patient recruitment target for the pivotal Phase 3 clinical trial of rexlemestrocel-L, its therapy for chronic low back pain. This is a significant operational milestone, confirming the trial is progressing as planned and on track for top-line results in mid-CY2027, followed by an anticipated regulatory filing in Q3 CY2027. The drug holds Regenerative Medicine Advanced Therapy (RMAT) designation, which could expedite FDA review. Given the company's projection of over $10 billion in potential peak annual revenue for this indication, this progress is highly material for Mesoblast. Traders will now closely monitor the trial's progress towards the expected data readout and subsequent regulatory submission.
At the time of this announcement, MESO was trading at $15.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $9.88 to $21.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.